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The Epstein-Barr virus (EBV) is associated with the development of numerous malignancies, including the
epithelial malignancy nasopharyngeal carcinoma (NPC). The viral oncoprotein latent membrane protein 1
(LMP1) is expressed in almost all EBV-associated malignancies and has profound effects on gene expression.
LMP1 acts as a constitutively active tumor necrosis factor receptor and activates multiple forms of the NF-B
family of transcription factors. LMP1 has two domains that both activate NF-B. In epithelial cells, LMP1
C-terminal activating region 1 (CTAR1) uniquely activates p50/p50-, p50/p52-, and p65-containing complexes
while CTAR2 activates canonical p50/p65 complexes. CTAR1 also uniquely upregulates the epidermal growth
factor receptor (EGFR). In NPC, NF-B p50/p50 homodimers and the transactivator Bcl-3 were detected on
the EGFR promoter. In this study, the role of NF-B p50 and Bcl-3 in LMP1-mediated upregulation of EGFR
was analyzed. In LMP1-CTAR1-expressing cells, chromatin immunoprecipitation detected p50 and Bcl-3 on
the NF-B consensus sites within the egfr promoter. Transient overexpression of p50 and Bcl-3 increased
EGFR expression, confirming the regulation of EGFR by these factors. Treatment with p105/p50 siRNA
effectively reduced p105/p50 levels but unexpectedly increased Bcl-3 expression and levels of p50/Bcl-3 com-
plexes, resulting in increased EGFR expression. These data suggest that induction of p50/p50/Bcl-3 complexes
by LMP1 CTAR1 mediates LMP1-induced EGFR upregulation and that formation of the p50/p50/Bcl-3
complex is negatively regulated by the p105 precursor. The distinct forms of NF-B that are induced by LMP1
CTAR1 likely activate distinct cellular genes.
The Epstein-Barr virus (EBV) is a ubiquitous human her-
pesvirus that infects more than 90% of the world’s population
and is associated with the development of numerous malignan-
cies, such as nasopharyngeal carcinoma (NPC) (12). Latent
membrane protein 1 (LMP1) is expressed in most EBV-asso-
ciated malignancies, is essential for EBV-induced B-lympho-
cyte transformation, and is the EBV oncogene (11). LMP1
induces focus formation in rodent fibroblasts, supports anchor-
age-independent growth of cells in soft agar, and supports
tumor formation in nude mice (12). LMP1 is an integral mem-
brane protein that acts as a constitutively active tumor necrosis
factor receptor. The C-terminal domain has two signaling re-
gions, CTAR1 and CTAR2, which constitutively associate with
tumor necrosis factor receptor-associated factors (TRAFs)
(24). Through its association with TRAFs, LMP1 initiates sig-
naling events including activation of the NF-B signaling cas-
cade (10, 14). The transcriptional up-regulation of multiple
cellular genes, such as icam-1, cd80, cd23, cd54, bcl-2, traf1,
a20, and egfr, is mediated by LMP1, and many of these genes
are known to be regulated by NF-B (14, 15, 22, 28, 32). In
epithelial cells, LMP1 activates at least three distinct types of
NF-B complexes (27).
NF-B is a family of transcription factors that regulate a
broad range of biological processes, including inflammation,
angiogenesis, cell cycle regulation, apoptosis, and oncogenesis
(7, 19). There are five mammalian NF-B family members,
p50, p52, p65 (RelA), c-Rel, and RelB. The NF-B family
members dimerize and bind NF-B consensus sequences in
cellular and viral promoters through their Rel homology do-
main. The p65, c-Rel, and RelB family members have trans-
activation domains that recruit transcriptional machinery to
promoters. The activation of NF-B family members is tightly
regulated through interactions with inhibitors of NF-B (IB),
which sequester NF-B members in the cytosol. Extracellular
stimuli, such as binding of tumor necrosis factor to its receptor,
induce a kinase cascade that ultimately results in phosphory-
lation, ubiquitination, and degradation of an IB, leading to
the release and nuclear translocation of bound NF-B. The
mammalian IBs include p105 (NFB1, the p50 precursor),
p100 (NFB2, the p52 precursor), IB, IB, IB, IBε,
and Bcl-3.
In epithelial cells, CTAR1 activates at least three different
dimeric forms of NF-B, including p50/p50 homodimers, p50/
p52 heterodimers, and complexes containing p65 (27). In con-
trast, CTAR2 induces only one complex that contains p65. The
distinct forms of NF-B induced by CTAR1 or CTAR2 are in
part mediated by different signaling pathways. Both CTAR1
and CTAR2 can activate NF-B through the canonical path-
way. This pathway is activated through the trimeric IB kinase
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(IKK) complex, which is composed of catalytic IKK and
IKK subunits and the regulatory IKK (NEMO) subunit (1,
5, 17, 29). Activation of the trimeric complex leads to phos-
phorylation and proteasome-dependent degradation of IB
and release of bound NF-B subunits. CTAR1 but not CTAR2
also activates NF-B through a noncanonical pathway where
IKK is activated by the NF-B-inducing kinase (NIK) inde-
pendently of the trimeric complex, and it then phosphorylates
p100 and mediates processing of p100 to p52 (1, 5, 17, 29).
CTAR1 also has the unique ability to upregulate the epidermal
growth factor receptor (EGFR) in an IB-dependent manner
through its interactions with TRAFs (20–23). Since only LMP1
CTAR1 activates p50/p50 homodimers and p50/p52 het-
erodimers, it is possible that EGFR upregulation is mediated
through activation of one of these forms. Neither p50 or p52
has transactivation domains; however, both can bind the onco-
protein Bcl-3 (2, 26). Bcl-3 is an unusual member of the IB
family in that it is most commonly expressed in the nucleus and
it has a transactivation domain that can provide transactivating
function to p50- or p52-containing complexes (2, 26).
Previous examination of xenografted NPC tumors detected
p50/p50 homodimers and Bcl-3 by chromatin immunoprecipi-
tation (ChIP) on the NF-B sites within the egfr promoter. In
this study, the unique ability of CTAR1 to activate p50/p50
homodimers and upregulate the EGFR was examined. The
data indicate that the induction of p50/p50 homodimers by
CTAR1 and the increased formation of complexes containing
Bcl-3 induce EGFR expression.
MATERIALS AND METHODS
Cell culture and reagents. C33A cervical carcinoma cells were cultured in
Dulbecco’s modified Eagle medium (Gibco) supplemented with 10% fetal bo-
vine serum (Sigma) and antibiotics at 37°C with 5% CO2. Cells were transfected
using the Fugene 6 transfection reagent (Roche) as directed by the manufac-
turer. Stable cell lines were made by transfecting the pCDNA3 vector control or
Myc-tagged LMP1 vectors into C33A cells. Forty-eight hours posttransfection,
cells were trypsinized, replated, and selected with 0.6 mg/ml G418-supplemented
medium. Stable cell lines were passaged in the presence of G418.
Cell extracts and Western blots. Cells were scrape harvested, washed once
with cold phosphate-buffered saline (PBS), and lysed with RIPA buffer (10 mM
Tris-HCl [pH 8.0], 140 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate
[SDS], 1% deoxycholic acid) supplemented with protease and phosphatase
inhibitor cocktails (Sigma). Equal amounts of protein were used for SDS-poly-
acrylamide gel electrophoresis (PAGE) and Western blotting. Primary antibod-
ies used for Western blots include anti-p105/p50, anti--actin, anti-Bcl-3, anti-c-
Myc, anti-IKK (Santa Cruz), anti-p65 (Rockland), and anti-p100/p52 (Upstate). A
rabbit antiserium raised against the carboxy-terminal 100 amino acids of the
EGFR fused to glutathione S-transferase (kindly provided by H. Shelton Earp)
was used to detect EGFR. Secondary antibodies used were horseradish peroxi-
dase-conjugated antimouse and antirabbit (Amersham Pharmacia) and antigoat
(DAKO). Blots were developed using the Pierce Supersignal West Pico chemi-
luminescence system.
Immunoprecipitations. Cells were scraped, washed with cold 1 PBS, and
lysed in IP buffer (1% Triton X-100, 0.5% of Nonidet P-40, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA) supplemented with protease inhibitor cocktail (Sigma).
Seventy-five micrograms of cellular extracts were precleared with GammaBind
Plus Sepharose (Amersham Pharmacia) for 2 h at 4°C. Precleared lysates were
immunoprecipitated with 1 g anti-p105/p50, anti-Bcl-3, anti-p100/p52, or iso-
type control antibody overnight. Immunoprecipitations were incubated with
GammaBind Plus Sepharose for 2 h at 4°C, washed two times, resuspended in
SDS-PAGE sample buffer, boiled, and used for SDS-PAGE and Western blots.
ChIP. ChIPs were performed as previously described (30). Briefly, 1  107
cells were scraped, resuspended in 50 ml DMEM, and cross-linked in 1% form-
aldehyde for 15 min at room temperature, followed by quenching with 120 mM
glycine. The cell pellet was washed with 1 PBS and lysed in RIPA buffer (10
mM Tris-HCl [pH 8.0], 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxy-
cholic acid) spiked with protease inhibitor cocktail (Sigma) for 30 min at 4°C.
Lysates were sonicated, clarified, and precleared with GammaBind Plus Sepha-
rose (Amersham Pharmacia). The supernatant was incubated without antibody,
with anti-p105/p50, or with anti-Bcl-3 (Santa Cruz) and nutated overnight at 4°C.
Lysates were immunoprecipitated with GammaBind Plus Sepharose and washed
four times, 5 min each, and DNA/protein was eluted from the beads with 1%
SDS, 1 Tris-EDTA at 65°C. The cross-linking was reversed overnight at 65°C
and samples treated with proteinase K at 37°C for 2 h. Sample DNAs were
purified with a QIAGEN PCR purification kit (QIAGEN) as directed by the
manufacturer. The NF-B sites in the egfr promoter were amplified by PCR with
the primer set 5 GGGGACCCGAATAAAGGAGCAGTTT 3 and 5 CTGA
GGAGTTAATTTCCGAGAGGGG 3 using Platinum Pfx polymerase (Invitro-
gen).
Nuclear extracts and EMSA. Nuclear extracts were used for electrophoretic
mobility shift assays (EMSAs). Nuclear extracts were made as previously de-
scribed (30). Briefly, cells were scraped, washed once with cold PBS, and lysed by
incubation in a hypotonic buffer (20 mM HEPES, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM dithiothreitol, protease, and phosphatase inhibitor cock-
tails [Sigma]) for 15 min on ice, followed by addition of Nonidet P-40 to a final
concentration of 1%. Nuclei were pelleted by low-speed centrifugation at 1,200
rpm for 10 min at 4°C. The nuclei were purified using the Optiprep reagent
(Sigma) as directed by the manufacturer, as previously described (30). Nuclei
were lysed with nuclear extraction buffer (20 mM Tris [pH 8.0], 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, protease inhibitor cocktail
[Sigma], and phosphatase inhibitor cocktail [Sigma]) with the salt concentration
adjusted to 400 mM with 5 M NaCl. Insoluble nuclear material was pelleted at
high speed for 10 min. EMSAs were performed as previously described (3).
An oligonucleotide (UV21) of the NF-B site from the H-2Kb gene (CA
GGGCTGGGGATTCCCCATCTCCCACAGTTTCACTTC) was labeled with
[-32P]dCTP using the Klenow fragment from DNA polymerase I. Five micro-
grams nuclear extracts were incubated with radiolabeled probe. For supershift
assays, 1 g antibody was incubated with extracts. Antibodies used were anti-
p105/p50, anti-Rel-B, anti-cRel (Santa Cruz), anti-p65 (Rockland), and anti-
p100/p52 (Upstate).
Quantitative reverse transcription-PCR. Total RNA was isolated from cells,
using an RNeasy minikit as directed by the manufacturer (QIAGEN). Total
RNA was quantified by spectrophometric measurements. Primer pairs were
designed using the Primer Express program (Applied Biosystems). The actin
primer set was 5 TCACCCACACTGTGCCCATCTACGA 3 and 5 CAGCG
GAACCGCTCATTGCCAATGG 3. The EGFR primer set was 5 TGCGTC
TCTTGCCGGAAT 3 and 5 GGCTCACCCTCCAGAAGC 3. Quantitative
reverse transcription-PCR was performed on DNase-treated RNA using the
Quantitect SYBR Green RT-PCR kit (QIAGEN) according to the manufactur-
er’s directions. Amplification of target sequences was detected using an ABI
7900HT sequence detection system (Applied Biosystems) and analyzed using
SDS 2.0 software (Applied Biosystems). The cycle threshold (CT) was deter-
mined as the number of PCR cycles required for a given reaction to reach an
arbitrary fluorescence value within the linear amplification range. The change in
CT (	CT) was determined between the same gene primer sets and different
samples, and the change in 	CT (		CT) was determined by adjusting for the
difference in the number of cycles required for actin to reach the CT. Since each
PCR cycle results in a twofold amplification of each product, the n-fold differ-
ence was determined as 2		CT. Each sample was analyzed in triplicate, and the
standard error was determined.
siRNA. Chemically synthesized small interfering RNA (siRNA) pools were
purchased from Dharmacon, targeting an irrelevant RNA, NF-B1, and Bcl-3.
Either 100 or 50 pmol siRNA was transfected into stable cells using a Lipo-
fectamine 2000 transfection reagent (Invitrogen) as directed by the manufac-
turer. Cells were harvested approximately 36 h posttransfection and were used
for Western blot analysis, quantitative reverse transcription-PCR, or immuno-
precipitations.
RESULTS
NF-B p50 binds Bcl-3 and immunoprecipitates with the
EGFR promoter. Previous studies revealed that LMP1 upregu-
lates the EGFR at the mRNA level (22). In EBV-positive NPC
tumors, NF-B p50 homodimers and Bcl-3 could be immuno-
precipitated with NF-B consensus sites in the egfr promoter
(30). In order to determine if LMP1 can induce the binding of
p50 and Bcl-3 to the egfr promoter, C33A cells stably express-
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ing the pCDNA3 vector control, full-length LMP1, LMP1(1-
231) (LMP1 that retains CTAR1 but not CTAR2; hereafter
referred to as 1-231), and LMP1(	187-351) (LMP1 that re-
tains CTAR2 but not CTAR1; hereafter referred to as 	187-
351) were examined by ChIP using primers that flank the
NF-B sites in the egfr promoter. In C33A stable cells, LMP1
expression and EGFR upregulation were confirmed by immu-
noblotting (Fig. 1A). As described previously, LMP1 activated
EGFR through CTAR1. The deletion mutant that retains
CTAR1, 1-231, strongly increased EGFR, while the deletion
mutant that retains CTAR2, 	187-351, did not upregulate
EGFR (Fig. 1A). By ChIP, precipitation with anti-p105/p50
weakly detected the NF-B sites in the egfr promoter in cells
expressing LMP1 and 1-231 (Fig. 1B, lanes 9 and 10) but not in
pCDNA3 cells or 	187-351 cells (Fig. 1B, lanes 8 and 11).
Bcl-3 was detected on the egfr promoter in 1-231-expressing
cells (Fig. 1B, lane 14) and weakly detected on the egfr pro-
moter in LMP1-expressing cells (Fig. 1B, lane 13). Bcl-3 was
not detected on the egfr promoter in pCDNA3- or 	187-351-
expressing cells (Fig. 1B, lanes 12 and 15). This ChIP corre-
lated with EGFR expression. In LMP1- and 1-231-expressing
cells, EGFR was upregulated and p50 and Bcl-3 were detected
on the egfr promoter. A very low level of EGFR was detected
in vector control cells and 	187-351-expressing cells, and Bcl-3
and p50 were not detected on the egfr promoter. The other
NF-B family members activated by LMP1, p65, p52, and RelB
were not detected on the egfr promoter (Fig. 1B, lanes 23 to
34). The absence of p52 on the egfr promoter indicates that the
unique activation of the noncanonical pathway by CTAR1
does not activate EGFR expression and that EGFR expression
is specifically correlated with the presence of p50 and Bcl-3 on
the egfr promoter.
Transient expression of p50 and Bcl-3 increase EGFR. In
order to determine if expression of p50 and/or Bcl-3 is suffi-
cient to mediate an increase in EGFR protein levels, C33A
cells were transiently transfected with vector control, p50,
Bcl-3, or p50 and Bcl-3. Expression of each was confirmed by
immunoblotting, and equal loading was confirmed with a -ac-
tin immunoblot (Fig. 2). EGFR expression levels were also
detected by immunoblotting. Transient expression of p50,
Bcl-3, or both detectably increased EGFR compared to results
with the vector control (Fig. 2). The intensities of the EGFR
bands shown in Fig. 2 were quantified using the Image J 1.32j
computer program and were listed immediately above the cor-
responding bands. This experiment has been repeated five
times; however, the values were calculated from the represen-
tative Western blot shown in Fig. 2. Cells expressing p50 alone
had an approximately twofold increase in the EGFR protein.
Cells expressing Bcl-3 alone had an approximately threefold
increase in the EGFR protein. Cells expressing both p50 and
Bcl-3 had an approximately fivefold increase in the EGFR
FIG. 1. NF-B p50 and Bcl-3 immunoprecipitate on the EGFR promoter. (A) EGFR and LMP1 expression was examined by immunoblotting
with C33A cells stably expressing Myc-tagged LMP1 or deletion mutant 1-231 or 	187-351 with anti-c-myc and anti-EGFR. The bottom panel is
a loading control. (B) A chromatin immunoprecipitation of p50, Bcl-3, p100/p52, p65, and RelB on the egfr promoter was performed with C33A
cells stably expressing LMP1 or deletion mutant 1-231 or 	187-351. Lanes 1 and 16 are DNA markers, lanes 2 and 17 are water PCR controls,
lanes 3 and 18 are genomic DNA from C33A cells, lanes 4 to 7 are immunoprecipitated in the absence of antibody, lanes 8 to 11 are
immunoprecipitated with anti-p105/p50 (-p105/p50), lanes 12 to 15 are immunoprecipitated with anti-Bcl-3 (-Bcl-3), lanes 19 to 22 are input
DNA from all four stable cell lines, lanes 23 to 26 are immunoprecipitated with anti-p100/p52 (-p100/p52), lanes 27 to 30 are immunoprecipitated
with anti-p65 (-p65), and lanes 31 to 34 are immunoprecipitated with anti-RelB (-RelB).
FIG. 2. Transient expression of p50 and Bcl-3 increases EGFR
protein. C33A cells were transiently transfected with p50 and Bcl-3,
and levels of EGFR were examined by immunoblotting. Equal loading
was confirmed with anti--actin. EGFR levels were measured by den-
sitometry of the immunoblot in the top panel. The Image J 1.32j
program was used to calculate the intensity of each band from one
Western blot. Pixel densities are listed above their corresponding
bands. The blot is representative of five independent experiments.
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protein. These data indicate that both p50 and Bcl-3 contribute
to upregulation of EGFR.
Increased EGFR expression requires canonical NF-B ac-
tivation. Several studies have determined that CTAR2 acti-
vates NF-B via the canonical pathway that is dependent upon
the trimeric IKK complex composed of IKK, IKK, and
IKK (NEMO). CTAR1 activates the NF-B canonical path-
way and the noncanonical pathway that induces processing of
p100 to p52. This processing is dependent on NIK and IKK
but is independent of the trimeric complex (1, 5, 29). A third
pathway has been studied, using knockout murine embryo fi-
broblasts, that was IKK dependent and considered atypical
canonical (17). To identify the pathways that contribute to
CTAR1-induced EGFR expression, dominant-negative forms
(DN) of NIK, IKK, and IKK were transiently expressed in
cells stably expressing 1-231. EGFR expression was analyzed
by quantitative reverse transcription-PCR. Expression of DN
NIK, IKK, and IKK did not significantly affect the trace
levels of EGFR in vector control cells (Fig. 3). In cells express-
ing CTAR1 (1-231), DN NIK also did not significantly changes
EGFR levels. DN IKK and DN IKK decreased EGFR ex-
pression in 1-231 cells, with the most dramatic decrease in-
duced by DN IKK. The inhibition of EGFR up-regulation by
both DN IKK and DN IKK suggests that CTAR1-mediated
effects on EGFR are regulated in part by the canonical path-
way. This is consistent with previously published data that
demonstrated that expression of a DN IB also inhibited
LMP1-induced EGFR expression (21). The lack of an effect by
the DN NIK indicates that the induction of EGFR by CTAR1
is not due to the noncanonical pathway.
DN IKK decreases nuclear p50 and EGFR protein. To
further characterize the forms of NF-B that contribute to
LMP1-mediated EGFR up-regulation, cells stably expressing
the pCDNA3 vector control, LMP1, 1-231, and 	187-351 were
transiently transfected with pCDNA3 vector control, wild-type
(wt) IKK, or the IKK DN double point mutant (SS 177, 181
AA) (DN IKK SSAA). Expression of LMP1, deletion mu-
tants, and IKK was confirmed by immunoblotting (Fig. 4,
middle two panels). Equal loading was assessed by Western
blotting (Fig. 4, bottom panel). NF-B activation was detected
by EMSA with a radiolabeled oligonucleotide probe (UV21)
with the NF-B consensus site from the MHC class I promoter,
using nuclear extracts (Fig. 4, top panel). EGFR levels were
measured by immunoblotting (Fig. 4, second panel). In C33A
epithelial cells, LMP1 and 1-231 activate p50 homodimers,
p50/p52 heterodimers, and p52/p65 heterodimers and 	187-
351 activates p52/p65 heterodimers (27). Transfection of wt
IKK and DN IKK into pCDNA3 control cells did not
change NF-B complex levels (Fig. 4, lanes 2 to 4). In both
LMP1- and 1-231-expressing cells, three complexes were de-
tected (Fig. 4, upper panel, lanes 5 and 8). The identities of
these complexes were confirmed by supershift analysis (data
not shown). Expression of DN IKK in LMP1 cells reduced all
complexes, and that in 1-231 cells almost completely elimi-
nated them. In particular, the strong nuclear p50/p50 ho-
modimer level was greatly diminished (Fig. 4, upper panel,
lanes 7 and 10). This decrease in nuclear p50/p50 homodimer
levels correlated with a decrease in EGFR levels (Fig. 4, lanes
7 and 10). In the CTAR2 containing 	187-351 cells, p52/p65
FIG. 3. Increased EGFR expression requires NF-B activation.
Stable cell lines expressing the pCDNA vector control or 1-231 were
transiently transfected with the vector control, DN NIK, IKK, or
IKK. RNA was harvested and used for quantitative reverse transcrip-
tion-PCR using primer sets for -actin and EGFR. The graph shows
the n-fold change from the level for pCDNA3 stable cells transfected
with the vector control and represents the average from separate
experiments. All samples are normalized to vector control results, and
EGFR levels were additionally normalized to the sample’s correspond-
ing -actin level. The bars represent the n-fold change in EGFR levels
from levels for pCDNA3 cells transfected with vector control. Each
sample was performed in triplicate, and the standard error is indicated.
The graph shown is representative of three independent experiments.
FIG. 4. DN IKK decreases nuclear p50 homodimers and EGFR
protein. C33A cells transiently transfected with pCDNA3 vector con-
trol, wild type IKK (WT IKK), or double-point-mutant (SS 177, 181
AA) DN IKK (DN IKK) were tested for nuclear NF-B complexes
by EMSA. Levels of EGFR, LMP1, and IKK were examined by
immunoblotting. The LMP1 expression panel is a composite from two
different gels. Equal loading was confirmed by using a loading control
(bottom panel). Lane 1 is a probe-alone control for the EMSA. Lanes
2 to 4 are pCDNA3 stable cells transiently transfected with pCDNA3,
wt IKK, or DN IKK; lanes 5 to 7 are LMP1 stable cells transfected
with pCDNA3, wt IKK, or DN IKK; lanes 8 to 10 are 1-231 stable
cells transfected with pCDNA3, wt IKK, or DN IKK, and lanes 11
to 13 are 	187-351 stable cells transfected with pCDNA3, wt IKK, or
DN IKK. Arrows identify the complexes. The EMSA and Western
blots are each representative of four independent experiments.
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heterodimers and p50 homodimers were detected (Fig. 4, up-
per panel, lanes 2 and 11, upper panel). Expression of wt IKK
in 	187-351 cells greatly increased the amount of the p65-
containing complex, indicating activation of the canonical
pathway. In addition, the p50/p50 homodimer was increased,
but this did not affect the trace levels of EGFR (Fig. 4, lanes 11
and 12, top two panels). Expression of the DN IKK in 	187-
351 cells eliminated the p52/65 form but surprisingly increased
the p50/50 homodimer. This increase did not increase the level
of EGFR. The effects of expression of the wt IKK and DN
IKK on the complexes detected by EMSA in CTAR1 suggest
that the IKK subunit contributes to p50/p50 homodimer ac-
tivation and LMP1-mediated EGFR up-regulation. The ab-
sence of EGFR up-regulation in the 	187-351 cells by either
the wt IKK or DN IKK, both of which increased the levels
of p50 homodimers, suggests that p50 homodimers are not
sufficient to activate EGFR expression and that an additional
activity is required that is not induced by 	187-351.
NF-B1 precursor negatively regulates p50/50 complexes
and EGFR expression. In order to determine if p50 and Bcl-3
are necessary for CTAR1-mediated EGFR upregulation, siRNAs
targeting NF-B1 and Bcl-3 were utilized to decrease p50 and
Bcl-3 expression. Cells were transfected with siRNA directed
against an irrelevant RNA, the p50 precursor, NF-B1 (p105),
Bcl-3, or both, and the effect on the cellular proteins was
determined by immunoblotting (Fig. 5). Transfection with NF-
B1 siRNA effectively decreased expression of the p50 precur-
sor protein, p105, and p50 (Fig. 5A, lane 2), and the decrease
was dose dependent (Fig. 5A, lanes 2 and 4). In contrast,
transfection with Bcl-3 siRNA did not affect the levels of cel-
lular Bcl-3 (Fig. 5A, lanes 3 and 4). Interestingly, transfection
with NF-B1 siRNA significantly increased the amount of
Bcl-3, suggesting that p105 or p50 may negatively regulate
Bcl-3. Transfection with NF-B1 siRNA or Bcl-3 siRNA did
not alter the other NF-B family member, p65 (Fig. 5A).
The regulation of the processing of p105 to p50 is distinct
from that of the processing of p100 to p52. In the pcDNA3
control cells, processed p50 was constitutively abundant while
processed p52 was detected at very low levels (Fig. 5B). LMP1
CTAR1 induces processing of p100 to p52 (1, 5, 17, 29). This
effect was apparent with greatly increased p52 in the 1-231-
expressing cells (Fig. 5B). In contrast, the relative amount of
p50/p105 over the pcDNA3 control was slightly increased by
LMP1 CTAR1.
To determine the effect of NF-B1 siRNA treatment on
EGFR upregulation, the siRNAs were transfected into vector
control cells or cells expressing the LMP1 mutant, 1-231, which
has the strongest activation of EGFR. NF-B p105 and p50
were effectively decreased by siRNA transfection in both
pCDNA3- and 1-231-expressing cells (Fig. 5B). The NF-B1
siRNA or Bcl-3 siRNA had a very slight effect on the total
amount of p100 and p52 and did not affect the LMP1-induced
processing of p100 (Fig. 5B). Surprisingly, siRNA-mediated
decrease of NF-B1 either alone or in combination with Bcl-3
increased EGFR expression compared to the irrelevant siRNA
control in 1-231-expressing cells (Fig. 5B, lanes 5, 6, and 8).
The effects of EGFR expression were quantified using the
Image J 1.32j computer program, and pixel intensities were
listed immediately above the corresponding bands. This exper-
iment was repeated three times; however, the values were
calculated from one representative Western blot. The in-
creased EGFR protein was not due to a decrease in the NF-
B-regulated inhibitory protein IB, as levels of IB were
not affected by the siRNA-mediated decrease of NF-B1 or
the increased Bcl-3 (Fig. 5B, bottom panel). However, the
increase in EGFR correlated with the increased Bcl-3 in the
NF-B1 siRNA-transfected 1-231 cells (Fig. 5A). It is known
that the precursors for p52 and p50 contain ankyrin repeats
and can function as repressors. The increase in EGFR induced
by the siRNA-mediated decrease in p105 likely reflects the
FIG. 5. NF-B1 siRNA negatively regulates p105/p50 expression and increases Bcl-3 and EGFR expression. (A) C33A cells were transfected
with 100 pmol irrelevant siRNA, 100 pmol NF-B1 siRNA, 100 pmol Bcl-3 siRNA, or 50 pmol NF-B1 and Bcl-3 siRNAs. Knockdown was
confirmed by immunoblotting. (B) C33A cells stably expressing pCDNA3 vector control or 1-231 were transfected with 100 pmol irrelevant siRNA,
100 pmol NF-B1 siRNA, 100 pmol Bcl-3 siRNA, or 50 pmol NF-B1 and Bcl-3 siRNAs. NF-B and EGFR protein levels were examined by
immunoblotting. The Image J 1.32j computer program was used to calculate the intensity of each EGFR band from one Western blot. Pixel density
values are listed above the corresponding bands. Units are arbitrary. The blot is representative of five independent experiments.
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inhibitory properties of p105 for the availability of the p50
homodimer complex.
To determine if the increase in EGFR protein levels after
siRNA treatment of NF-B1 and Bcl-3 occurred at the RNA
level, quantitative reverse transcription-PCR was performed
on vector control cells and cells expressing 1-231 transiently
transfected with siRNA of irrelevant RNA, NF-B1, and Bcl-3.
PCR was performed with actin-specific primers for RNA in-
tegrity control and EGFR-specific primers. Each sample was
normalized to RNA from cells expressing 1-231 transfected
with irrelevant siRNA. The graph in Fig. 6 shows the n-fold
change over the level for 1-231 with irrelevant siRNA and
represents results from four independent experiments. The
actin levels were unchanged and therefore confirm the integ-
rity of the RNA (data not shown). Cells expressing 1-231 and
transfected with NF-B1 siRNA had an approximately three-
fold increase of EGFR RNA over that for 1-231-expressing
cells. Bcl-3 siRNA expression alone or in combination with
NF-B1 siRNA did not significantly change EGFR RNA (Fig.
6). These results confirmed the immunoblot analysis and sug-
gested that siRNA degradation of cellular NF-B1 increased
EGFR protein and RNA levels and that this correlated with
the increase in Bcl-3.
Increased Bcl-3 coimmunoprecipitates with NF-B1 after
transfection with NF-B1 siRNA. To determine the effect of
an siRNA-mediated decrease of NF-B1 and Bcl-3 on forma-
tion of the p50/Bcl-3 complex, coimmunoprecipitation of p105/
p50, p100/p52, and Bcl-3 was analyzed. P105 and p50 did not
immunoprecipitate with anti-p100/p52 (Fig. 7A, lanes 8 to 12).
A considerable level of NF-B p50 immunoprecipitated with
anti-Bcl-3 in vector control pCDNA3 cells (Fig. 7A, lane 13),
and increased p50 immunoprecipitated with anti-Bcl-3 in 1-231
cells treated with irrelevant siRNA (Fig. 7A, lane 14). Al-
though the amount of p50 was greatly reduced by transfection
with NF-B1 siRNA (Fig. 5A), the amount of p50 that coim-
munoprecipitated with Bcl-3 was only slightly affected (Fig. 7A,
lanes 15 and 17). The siRNA-mediated decrease of p105/p50
and the consequential increase in Bcl-3 resulted in more Bcl-3
FIG. 6. NF-B1 siRNA increases EGFR RNA. C33A cells stably
expressing vector control or 1-231 were transfected with 100 pmol
irrelevant siRNA (
), 100 pmol NF-B1 siRNA (NF-B1), 100 pmol
Bcl-3 siRNA (Bcl-3), or 50 pmol NF-B1 and Bcl-3 siRNAs (NF-
B1Bcl-3). -Actin and EGFR levels were examined with quantita-
tive reverse transcription-PCR. All samples were normalized to results
for 1-231 stable cells transfected with irrelevant siRNA, and each
EGFR PCR was further normalized to the -actin level in its corre-
sponding sample. The graph shows n-fold change in EGFR RNA level
over that for 1-231 with irrelevant siRNA and is a representative result
from five independent experiments.
FIG. 7. Increased Bcl-3 coimmunoprecipitates with NF-B1 after
transfection with NF-B1 siRNA. (A) Coimmunoprecipitation of p105/
p50 with p100/p52 and Bcl-3 was measured after knockdown with 100
pmol irrelevant siRNA, 100 pmol NF-B1 siRNA, 100 pmol Bcl-3 siRNA,
or 50 pmol NF-B1 and Bcl-3 in C33A cells stably expressing pCDNA3 or
1-231. Stable cells were transfected with the siRNA indicated above the
immunoblot. Lanes 1 and 2 are a direct load of protein lysates from
pCDNA3 and 1-231 stable cells. Lanes 3 to 7 are immunoprecipitated
with rabbit immunoglobulin G (IgG) isotype control, lanes 8 to 12 are
immunoprecipitated with anti-p100/p52 (-p100/p52), and lanes 13 to 17
are immunoprecipitated with anti-Bcl-3 (-Bcl-3). All immunoprecipi-
tates were immunoblotted with anti-p50. (B) Coimmunoprecipitation of
Bcl-3 with anti-p105/p50 (-p105/p50) and anti-p100/p52 was measured
after knockdown with siRNAs as described for panel A with C33A cells
stably expressing pCDNA3 or 1-231. Stable cells were transfected with the
siRNA indicated above the immunoblot. Lanes 1 and 2 are direct loads of
protein lysates from pCDNA3 and 1-231 stable cells. Lanes 3 to 7 are
immunoprecipitated with goat IgG isotype control, lanes 8 to 12 are
immunoprecipitated with anti-p105/p50, and lanes 13 to 17 are immuno-
precipitated with anti-p100/p52. The complexes were immunoblotted with
anti-Bcl-3. (C) Coimmunoprecipitation of anti-p100/p52 with anti-p105/
p50 and Bcl-3 was measured after siRNA knockdown as described for
panel A in pCDNA3 and 1-231 stable C33A cells. Stable cells were
transfected with the siRNA indicated above the immunoblot. Lanes 1 and
2 are a direct load of protein lysates from pCDNA3 and 1-231 stable cells.
Lanes 3 to 7 are immunoprecipitated with mouse IgG isotype control,
lanes 8 to 12 are immunoprecipitated with anti-p105/p50, and lanes 13 to
17 are immunoprecipitated with anti-Bcl-3. The immunoprecipitates were
immunoblotted with anti-p52.
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in complexes immunoprecipitated with anti-p105/p50 (Fig. 7B,
lanes 10 and 12). Immunoprecipitation with anti-p100/p52 con-
firmed that in C33A cells expressing 1-231, p100/p52 did not
bind p50 (Fig. 7A, lanes 8 to 12) or Bcl-3 (Fig. 7B, lanes 13 to
17). NF-B p100/p52 also did not immunoprecipitate with ei-
ther anti-p105/p50 or anti-Bcl-3 (Fig. 7C, lanes 8 to 17). These
data indicate that transfection of NF-B1 siRNA did not in-
duce formation of p52/Bcl-3 complexes. These results reveal
that despite a significant decrease in the overall pool of p105/
p50, the remaining p50 binds more efficiently to Bcl-3 in the
absence of p105 and that the increased EGFR expression cor-
related with increased complex formation between p50 and
Bcl-3.
DISCUSSION
The data presented in this study indicate that the LMP1
CTAR1 domain induces the binding of NF-B p50 and Bcl-3
to the NF-B sites in the egfr promoter in C33A cells and this
correlated with EGFR upregulation (Fig. 1). It has previously
been determined that egfr has five NF-B consensus binding
sites in its promoter, and p50 specifically binds to four of those
sites (25). Furthermore, it was determined that in xenografted
NPCs, both p50 and Bcl-3 coimmunoprecipitate with three of
those sites in the egfr promoter (30). The data in this paper
support the in vivo model in which p50 and Bcl-3 are present
on the egfr promoter when CTAR1 is present. Of note, anti-
p100/p52, anti-p65, and anti-RelB did not immunoprecipitate
the NF-B sites in the egfr promoter, indicating that in C33A
cells, these family members do not promote EGFR upregula-
tion. The absence of p52 or RelB confirms that the upregula-
tion of EGFR by CTAR1 was not mediated by the effects of
CTAR1 on the noncanonical NF-B pathway.
Expression of p50 and Bcl-3 in the absence of LMP1 also
increased EGFR expression (Fig. 2). NF-B p50/p50 and p52/
p52 homodimers have been thought of as being transcription-
ally inhibitory because neither p50 nor p52 has transactivation
domains. NF-B p50 can bind the transcriptionally inhibitory
histone deacetylase 1 (34). However, if bound to Bcl-3, p50/p50
and p52/p52 homodimers may be transcriptionally active (2,
33). It has been shown that p52/Bcl-3 complexes transcription-
ally upregulated cyclin D1 and promoted cell cycle progression
more efficiently than other NF-B family members (33).
NF-B p50 may also directly activate cellular promoters, and
the antiapoptotic protein Bcl-2, which is also upregulated by
LMP1, can be transcriptionally regulated by p50 homodimers
(13, 28). In EBV-positive samples of NPC, p50/p50 ho-
modimers preferentially bound Bcl-3 and did not bind histone
deacetylase 1, and both p50 and Bcl-3 were detected by ChIP
on the EGFR promoter (30).
NF-B activity is controlled by a kinase cascade that begins
with an extracellular signal that leads to activation of the IKK
complex and phosphorylation of IB. The IKK complex is a
trimeric complex consisting of two catalytic domains, IKK
and IKK, and a regulatory domain, IKK (NEMO). IKK is
the dominant kinase in phosphorylation of IB (7). NIK can
also phosphorylate and activate IKK, which can phosphory-
late the p52 precursor, p100, in an IKK-independent manner
to produce p52. LMP1 CTAR1 activates NF-B through both
IKK-dependent and noncanonical IKK-independent path-
ways, mediates NF-B release from IB, and induces phosphor-
ylation of p100 followed by processing of p100 to p52 (1, 5, 17,
29). In contrast, CTAR2 induces canonical NF-B activation
through the IKK-dependent IKK complex.
The role of NF-B was confirmed in this study, since trans-
fection of DN IKK and IKK decreased EGFR in cells ex-
pressing 1-231 (Fig. 3 and 4). These findings confirm the pre-
vious inhibition of LMP1-mediated EGFR upregulation by a
DN IB (20). In 1-231 cells, transient transfection of DN
IKK decreased EGFR RNA threefold, while transient trans-
fection of DN NIK did not change EGFR and DN IKK
decreased EGFR RNA by approximately one-third. The non-
canonical processing and activation of p52 by CTAR1 is de-
pendent upon NIK and IKK; therefore, the minimal effects of
DN NIK and DN IKK and the more-pronounced inhibition
by DN IKK further indicate that the CTAR1 upregulation of
EGFR is not mediated by p52 and the noncanonical pathway.
The data presented here indicate that the unique CTAR1
upregulation of EGFR is linked in part to its induction of p50
homodimers and that IKK is a significant factor in the regu-
lation of EGFR by CTAR1.
However, the increased levels of p50 homodimers induced
by wt IKK and DN IKK in cells expressing CTAR2-contain-
ing 	187-351 LMP1 were not sufficient to induce EGFR ex-
pression. This suggests that other signaling pathways activated
by LMP1 CTAR1 contribute to EGFR upregulation in con-
junction with NF-B. A recent publication indicated that
GSK3 phosphorylates Bcl-3 and mediates its degradation (31).
LMP1 activates Akt through CTAR1, and phosphorylated,
inactive GSK3 is elevated in EBV-infected cells (4, 18). The
activation of Akt and inactivation of GSK3 by LMP1 may
affect the activity of Bcl-3.
The siRNA-mediated decrease in p105/p50 surprisingly in-
creased levels of Bcl-3 and p50/Bcl-3 complexes and correlated
with increased levels of EGFR (Fig. 6 and 7). Although the
siRNA-mediated decrease in p50 could affect the amount of
IB proteins, a change in IB was not detected (Fig. 5B).
NF-B p105 is the p50 precursor and is also considered an IB
since it can act as an inhibitory molecule by binding and se-
questering p50 in the cytoplasm (6, 8, 9, 16). The decrease in
the inhibitory p105 likely increases the availability of the re-
maining processed p50, which may complex with Bcl-3 more
efficiently in the absence of p105 (Fig. 7). Bcl-3 can also inter-
act with p52 to form a transcriptionally active complex; how-
ever, p52 was not detected on the egfr promoter in C33A cells
(Fig. 1) and p52 was not detected in a complex with p50 or
Bcl-3 by coimmunoprecipitation in C33A cells (Fig. 7). These
findings support the previous detection of only p50 and Bcl-3
on the egfr promoter in xenografted NPC and indicate that
p50/Bcl-3 more likely mediates EGFR upregulation (5, 30).
The data presented in this article suggest a new role for NF-B
p50/Bcl-3 complexes as transcriptional activators and indicate
that this complex likely functions in the transcriptional regu-
lation of EGFR.
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